BioSocieties

, Volume 2, Issue 1, pp 21–40 | Cite as

Clinical Trials Offshored: On Private Sector Science and Public Health

  • Adriana Petryna
Article

Abstract

This article addresses the offshoring of clinical trials to middle- and low-income countries, and the complicated ways in which they have become integral to public health and quality of care in these contexts. I focus on the operations of United States-based contract research organizations (CROs), which make up a specialized global industry focusing on the recruitment of human subjects and investigators; they are key players in an outsourced world of clinical development ‘service providers’. To get an on-the-ground understanding of the offshored clinical trial, I worked with regulators, health services administrators, and research clinicians in Eastern Europe and Latin America, two clinical trial market ‘growth regions’. By addressing the strategies of evidence-making that inform clinical trial offshoring, this article identifies the context-specific calculations by which experimental groups are being identified. It also addresses aspects of the clinical trial operational model, in which the failure to predict safety outcomes or a paradigm of expected failure is being exported along with the offshored trial. By highlighting the uncertainties of clinical research, this article points to gaps in systems of human protection as it considers new forms of accountability in private sector science and public health.

Keywords

global pharmaceuticals clinical trial environments offshoring ethical variability human subjects research ethics 

References

  1. Abramson J. (2004). Overdosed America: The broken promise of American medicine. New York: HarperCollins.Google Scholar
  2. Angell M. (1988). Ethical imperialism? Ethics in international collaborative clinical research. New England Journal of Medicine, 319, 1081–1083.CrossRefGoogle Scholar
  3. Angell M. (1997). The ethics of clinical research in the Third World. New England Journal of Medicine, 337, 847–849.CrossRefGoogle Scholar
  4. Angell M. (2000). Investigators’ responsibilities for human subjects in developing countries. New England Journal of Medicine, 342, 967–968.CrossRefGoogle Scholar
  5. Angell M. (2005). The truth about the drug companies: How they deceive us and what to do about it. New York: Random House.Google Scholar
  6. Angell M. (2006). Your dangerous drugstore. New York Review of Books, 53(10). URL (accessed February 2007): www.nybooks.com/articles/19055
  7. Avorn J. (2004). Powerful medicines: The benefits, risks, and costs of prescription drugs. New York: Knopf.Google Scholar
  8. Bayer R. (1998). The debate over maternal-fetal HIV transmission prevention trials in Africa, Asia, and Caribbean: Racist exploitation or exploitation of racism? American Journal of Public Health, 88, 567–570.CrossRefGoogle Scholar
  9. Biehl J. (2001). Technology and affect: HIV/AIDS testing in Brazil. Culture, Medicine and Psychiatry, 25, 87–129.CrossRefGoogle Scholar
  10. Biehl J. (2006). Pharmaceutical governance. In Petryna A. Lakoff A. & Kleinman A. (Eds), Global pharmaceuticals: Ethics, markets, practices. Durham, NC: Duke University Press.Google Scholar
  11. Botbol-Baum M. (2000). The shrinking of human rights: The controversial revision of the Helsinki Declaration. HIV Medicine, 1, 238–245.CrossRefGoogle Scholar
  12. Christakis N. (1992). Ethics are local: Engaging cross-cultural variation in the ethics for clinical research. Social Science and Medicine, 35, 1079–1091.CrossRefGoogle Scholar
  13. Cohen L. (1999). Where it hurts: Indian material for an ethics of organ transplantation. Special issue on ‘Bioethics and beyond’, Daedalus, 128, 135–165.Google Scholar
  14. Crouch R.A., & Arras J.D. (1998). AZT trials and tribulations. Hastings Center Report, 28, 26–34.CrossRefGoogle Scholar
  15. Das V. (1999). Public good, ethics, and everyday life: Beyond the boundaries of bioethics. Special issue on ‘Bioethics and beyond’, Daedalus, 128, 99–134.Google Scholar
  16. Das V., & Das R.K. (2006). Pharmaceuticals in urban ecologies: The register of the local. In Petryna A. Lakoff A. & Kleinman A. (Eds), Global pharmaceuticals: Ethics, markets, practices. Durham, NC: Duke University Press.Google Scholar
  17. de Zulueta P. (2001). Randomised placebo-controlled trials and HIV-infected pregnant women in developing countries: Ethical imperialism or unethical exploitation? Bioethics, 15, 289–311.CrossRefGoogle Scholar
  18. Dickersin K., & Rennie D. (2003). Registering clinical trials. Journal of the American Medical Association, 290: 516.CrossRefGoogle Scholar
  19. Epstein S. (1996). Impure science: AIDS, activism, and the politics of knowledge. Berkeley: University of California Press.Google Scholar
  20. Etkin N. (1999). The rational basis of ‘irrational’ drug use: Pharmaceuticals in the context of development. In R.A. Hahn (Ed.), Anthropology in public health: Bridging differences in culture and society, 165–182. New York: Oxford University Press.Google Scholar
  21. Farmer P. (1999). Infections and inequalities: The modern plagues. Berkeley: University of California Press.Google Scholar
  22. Farmer P. (2002). Can transnational research be ethical in the developing world? The Lancet, 360, 1301–1302.CrossRefGoogle Scholar
  23. FDA (Food and Drug Administration) (2004). Innovation/stagnation: Challenge and opportunity on the critical path to new medical products. March. Washington, DC: Dept of Health & Human Services.Google Scholar
  24. Geertz C. (2000 [1984]). Anti anti-relativism. In Available light: Anthropological reflections on philosophical topics, 42–67. Princeton, NJ: Princeton University Press.Google Scholar
  25. Goozner M. (2004). The $800 million pill: The truth behind the cost of new drugs. Berkeley: University of California Press.Google Scholar
  26. Gorman J. (2004). The altered human is already here. New York Times, 6 April: F1.Google Scholar
  27. Guess H.A., Kleinman A., Kusek J.W., & Engel L.W. (Eds) (2002). The science of the placebo: Toward an interdisciplinary research agenda. London: BMJ Books.Google Scholar
  28. Harkness J.M. (1996). Nuremberg and the issue of wartime experiments on US prisoners: The Green Committee. Journal of the American Medical Association, 276, 1672–1675.CrossRefGoogle Scholar
  29. Healy D. (2003). Lines of evidence on the risks of suicide with selective serotonin reuptake inhibitors. Psychotherapy and Psychosomatics, 72, 71–79.CrossRefGoogle Scholar
  30. Juni P., Nartey L., Reichenbach S., Sterchi R., Dieppe P.A., & Egger M. (2004). Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. The Lancet, 364, 2021–2029.CrossRefGoogle Scholar
  31. Kahn J.P., Mastroianni A.C., & Sugarman J. (1998). Beyond consent: Seeking justice in research. Oxford: Oxford University Press.Google Scholar
  32. Kassirer J.P. (2004). On the take: How medicine's complicity with big business can endanger your health. Oxford: Oxford University Press.Google Scholar
  33. Kent D., Mwamburi M., Bennish M., Kupelnick B., & Ioannidis J. (2004). Clinical trials in sub-Saharan Africa and established standards of care: A systematic review of HIV, tuberculosis, and malaria trials. Journal of the American Medical Association, 292, 237–242.CrossRefGoogle Scholar
  34. Kim J.Y., Mukherjee J.S., Rich M.L., Mate K., Bayona J., & Becerra M.C. (2003). From multidrug-resistant tuberculosis to DOTS expansion and beyond: Making the most of a paradigm shift. Tuberculosis, 83, 59–65.CrossRefGoogle Scholar
  35. Lasagna L. Prisoner subjects and drug testing. Fed Proc 1977 Sept 36(10): 2349–2351.Google Scholar
  36. Lemmens T., & Freedman B. (1997). Ethics review for sale? Conflict of interest and commercial research ethics review. Milbank Quarterly, 78, 547–584.CrossRefGoogle Scholar
  37. Lexchin J., Bero L.A., Djulbegovic B., & Clark O. (2003). Pharmaceutical industry sponsorship and research outcome and quality: Systematic review. British Medical Journal, 326, 1167–1170.CrossRefGoogle Scholar
  38. Lurie P., & Wolfe S.M. (1998). Unethical trials of interventions to reduce perinatal transmission of the human immunodeficiency virus in developing countries. New England Journal of Medicine, 337, 853–855.CrossRefGoogle Scholar
  39. Lurie P., & Wolfe S.M. (2000). Letter to the National Bioethics Advisory Commission regarding their report on the challenges of conducting research in developing countries (HRG Publication #1545). URL (accessed January 2007): www.citizen.org/publications/release.cfm?ID=6746
  40. Macklin R. (1999). Against relativism: Cultural diversity and the search for ethical universals in medicine. Oxford: Oxford University Press.Google Scholar
  41. Marks H. (1997). The progress of experiment: Science and therapeutic reform in the United States, 1900–1990. Cambridge: Cambridge University Press.Google Scholar
  42. Marks H. (2000). Where do ethics come from? The role of disciplines and institutions. Paper presented at the Conference on ‘Ethical Issues in Clinical Trials’, University of Alabama at Birmingham, 25 February.Google Scholar
  43. Marks H. (2002). Commentary. 3rd Annual W.H.R. Rivers Workshop, ‘Global Pharmaceuticals: Ethics, Markets, Practices’, Harvard University, 19– 21 May.Google Scholar
  44. Masters B., & Kaufman M. (2004) Painful withdrawal for makers of Vioxx. Washington Post 18 October, A01.Google Scholar
  45. Moynihan R., & Cassels A. (2005). Selling sickness: How the world's biggest pharmaceutical companies are turning us all into patients. New York: Nation Books.Google Scholar
  46. Office of the Inspector General, Department of Health and Human Services (2001). The globalization of clinical trials: A growing challenge in protecting human subjects. Boston, MA: Office of Evaluation and Inspections.Google Scholar
  47. Petryna A. (2002). Life exposed: Biological citizens after Chernobyl. Princeton, NJ: Princeton University Press.Google Scholar
  48. Petryna A. (2005). Ethical variability: Drug development and the globalization of clinical trials. American Ethnologist, 32, 183–197.CrossRefGoogle Scholar
  49. Petryna A. (forthcoming) The human subjects research enterprise. Princeton, NJ: Princeton University Press.Google Scholar
  50. Petryna A., & Kleinman A. (2006). The pharmaceutical nexus: An introduction. In A. Petryna A. Lakoff & A. Kleinman (Eds), Global pharmaceuticals: Ethics, markets, practices. Durham, NC: Duke University Press.CrossRefGoogle Scholar
  51. Rothman D. (2000). The shame of medical research. New York Review of Books, 47(19), 60–64.Google Scholar
  52. Sim I., & Detmer D.E. (2005). Beyond trial registration: A global trial bank for clinical trial reporting. PLoS Medicine, 2, e365.CrossRefGoogle Scholar
  53. Temple R. (2002). Placebo-controlled trials and active controlled trials: Ethics and inference. In H.A. Guess A. Kleinman J.W. Kusek & L.W. Engel (Eds), The science of the placebo: Toward an interdisciplinary research agenda, 209–226. London: BMJ Books.Google Scholar
  54. Wardell W., & Lasagna L. (1975). Regulation and drug development. Washington, DC: American Enterprise Institute for Public Policy Research.Google Scholar

Copyright information

© London School of Economics and Political Science 2007

Authors and Affiliations

  • Adriana Petryna
    • 1
  1. 1.Department of AnthropologyUniversity of PennsylvaniaUSA

Personalised recommendations